[{"orgOrder":0,"company":"Lonza Group","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"RP-L201","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Lonza","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Lonza"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Xortx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ XORTX Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ XORTX Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Group \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Moderna"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Wnt Activating Antibodies","moa":"WNT signalling pathway","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Surrozen"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"KSI-301","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Lonza Group \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Kodiak Sciences"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Humanigen"},{"orgOrder":0,"company":"Lonza Group","sponsor":"LamKap Bio Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"NILK-2301","moa":"CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ LamKap Bio Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ LamKap Bio Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ AstraZeneca"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Altimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"AdCOVID","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Altimmune"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Immunology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lonza Group \/ Aurinia","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Aurinia"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Capricor","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Capricor"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Aruvant","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Aruvant"},{"orgOrder":0,"company":"Lonza Group","sponsor":"PsiVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Ixovex-1","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lonza Group \/ PsiVac","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ PsiVac"},{"orgOrder":0,"company":"Lonza Group","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"ATYR2810","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ aTyr Pharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Autologous CAR-T Cells","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Leucid Bio"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Affinia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Anc80L65","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Lumbar Puncture","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Dovitinib","moa":"FGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Not Applicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Cantrixil","moa":"Selective mitochondrial electron transfer","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal","sponsorNew":"Lonza Group \/ Lonza","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Lonza"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Pembrolizumab","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Pierre Fabre"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Cristal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Cristal Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ Cristal Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"McSAF","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ McSAF","highestDevelopmentStatusID":"3","companyTruncated":"Lonza Group \/ McSAF"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Simris Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-Drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"2","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"ABL Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ ABL Bio"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"STx-02","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Group \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Vaxcyte"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lonza Group \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Lonza Group \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"12","companyTruncated":"Lonza Group \/ Lonza Group"}]
Find Clinical Drug Pipeline Developments & Deals by Lonza Group
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
